Search clinical trials for: ozanimod

Total 56 results

The University of Texas at Dallas
Texas Institute for Neurological Disorders

Not yet recruiting

Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS

Multiple Sclerosis

United States
University of California, San Diego

Recruiting

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

Ulcerative Colitis | Ulcerative Colitis Chronic Moderate

United States
Geert D'Haens
Bristol-Myers Squibb

Not yet recruiting

Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study (ULTRAZ)

Ulcerative Colitis
Bristol-Myers Squibb

Not yet recruiting

A Lactation Study in Women Receiving Treatment With Ozanimod

Lactating Women | Breastfed Infants
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

Ulcerative Colitis

Korea, Republic of
Bristol-Myers Squibb

Not yet recruiting

A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

Ulcerative Colitis
First Affiliated Hospital of Zhejiang University

Recruiting

Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (CHA)

Acute Myeloid Leukemia, Adult

China
Bristol-Myers Squibb

Recruiting

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (AppreZiate)

Relapsing-remitting Multiple Sclerosis (RRMS)

Spain
Beth Israel Deaconess Medical Center

Not yet recruiting

Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis

Ulcerative Colitis

United States
I.R.C.C.S. Fondazione Santa Lucia

Recruiting

Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis. (OMNIAOMS)

Multiple Sclerosis

Italy
Insel Gruppe AG, University Hospital Bern
Bristol-Myers Squibb

Recruiting

Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success (COMMIT)

Ulcerative Colitis

Switzerland
Biogen

Recruiting

A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Multiple Sclerosis

United States
Bristol-Myers Squibb

Recruiting

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (SWITCH - ITA)

Multiple Sclerosis, Relapsing-Remitting

Italy
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis

China, Taiwan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Crohn Disease

United States, Belgium, Hungary, France, Canada, Spain, Australia, Germany, Poland, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis (COLIBRI)

Colitis, Ulcerative

Germany
Bristol-Myers Squibb

Recruiting

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Colitis, Ulcerative

United States
Bristol-Myers Squibb

Recruiting

A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®) (OzEAN)

Multiple Sclerosis, Relapsing-Remitting

Germany
Brigham and Women's Hospital
Bristol-Myers Squibb

Not yet recruiting

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

Multiple Sclerosis | Fatigue
Neuromed IRCCS
University of Rome Tor Vergata

Not yet recruiting

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

Healthy | Neuromyelitis Optica | Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Bristol-Myers Squibb

Recruiting

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Multiple Sclerosis

United States, Germany
Bristol-Myers Squibb

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Colitis, Ulcerative

United States, Belgium, Germany, Japan, France, Russian Federation, Spain, Poland, Australia, Canada, Israel, United Kingdom
Kessler Foundation
Celgene; Hackensack Meridian Health; St. Barnabas Medical Center

Recruiting

An Examination of Cognitive Fatigue Using Functional Neuroimaging

Multiple Sclerosis, Relapsing-Remitting

United States
The Cleveland Clinic
University of Nottingham

Recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Johns Hopkins University
Patient-Centered Outcomes Research Institute; National Multiple Sclerosis Society

Recruiting

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)

Multiple Sclerosis, Relapsing-Remitting

United States
Celgene

Recruiting

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, ... and more
Celgene

Recruiting

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Poland, Romani... and more
Celgene

Recruiting

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Australia, Argentina, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Poland, Romani... and more
Centre de Recherche de l'Institut Universitaire...
Bristol-Myers Squibb; Celgene

Terminated

COVID-19 Ozanimod Intervention Study (COZI)

COVID-19

Canada
Celgene

Completed

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Multiple Sclerosis

United States, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Moldova, Republic of, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South... and more
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
Celgene

Active, not recruiting

To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Celgene

Completed

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Spain, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Se... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

Multiple Sclerosis

United States
Celgene

Active, not recruiting

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

Multiple Sclerosis

United States, Canada, Puerto Rico
Celgene

Active, not recruiting

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Greece, United Kingdom, Hungary, Belgium, Slovakia, Bulgaria, Italy, Australia, Israel, Belarus, Romania, Ukraine
Celgene

Completed

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Taste Assessment of Ozanimod

Healthy Volunteers

United States
Bristol-Myers Squibb

Active, not recruiting

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety (ORION)

Multiple Sclerosis, Relapsing-Remitting

United States
Monash University

Enrolling by invitation

Relationship Between Oral DMT Burden and Adherence in MS (STATURE)

Multiple Sclerosis | Adherence, Medication

Australia
Celgene

Completed

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

Liver Diseases | Digestive System Diseases

United States
Celgene

Completed

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Korea, Republic of, United States, Belgium, Israel, Netherlands, Australia, Germany, Hungary, New Zealand, Italy, Canada, Bulgaria, Croatia, United Kingdom, Argentina, Austria, Belarus, Czechia, Georgia, Moldova, Republic of, Po... and more
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis (Touchstone)

Ulcerative Colitis

Netherlands, United States, Israel, Australia, Korea, Republic of, New Zealand, Hungary, Poland, Slovakia, Ukraine, Canada, Bulgaria, Greece, Russian Federation, Belgium
Celgene

Completed

A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects

Healthy Volunteer

China
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (RADIANCE)

Relapsing Multiple Sclerosis

Spain, United States, United Kingdom, Croatia, Serbia, Belarus, Hungary, Bulgaria, Poland, Italy, Ukraine, Greece, Belgium, Georgia, Bosnia and Herzegovina, Moldova, Republic of, Romania, Russian Federation, Slovakia, South Africa and more
Celgene

Completed

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (RADIANCE)

Relapsing Multiple Sclerosis

Serbia, United States, Poland, Spain, Belgium, Bulgaria, Georgia, Greece, Romania, Russian Federation, Ukraine, Hungary, Italy
Celgene

Completed

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Poland, Ukraine, Hungary, Canada
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Celgene

Completed

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

Healthy Volunteers

United States

Search clinical trials for: ozanimod

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations